Product Detail  

Salesperson：zora

whatsapp：+85269492373

Email：zora@anymang.cn

Why choose us

Our company has independent factories, mass production of pharmaceutical intermediates, organic intermediates and other raw materials, widely used in medicine, health care products, cosmetics, nutritional supplements, food additives and other fields.
Our company adheres to the business philosophy of integrity and cooperation. scientific innovation and service first.With absolute quality assurance as the purpose and perfect service system as the basis, our company provides efficient and satisfactory consulting services, sincerely welcomes your business inquiries,and looks forward to working with you to create a new future.  
Key Products:
Our primary focus encompasses a range of products, including weight loss peptides, medicinal peptides, cosmetic peptides, and customized peptides. Notable among our weight loss peptide offerings are Semaglutide, Tirzepatide, Retatrutide, and others.

Mechanism of Action & Advantages

Triple Receptor Agonist: As a triple agonist targeting GLP-1, GIP, and glucagon receptors, Retatrutide enables multi-pathway synergy to regulate blood glucose, energy expenditure, and appetite for comprehensive metabolic control.

Potent Weight Loss & Glucose Control: Clinical data show its weight reduction and glycemic benefits are significantly superior to single or dual receptor agonists, offering a more robust treatment option for severe obesity and type 2 diabetes.

Broader Metabolic Benefits: Beyond weight and glucose, studies indicate positive effects on cardiovascular metabolic markers like blood pressure and lipids.

Clinical Trials & Safety Profile ​

Phase II & III Clinical Trials: In multiple large-scale, randomized, double-blind, placebo-controlled trials, Retatrutide demonstrated outstanding efficacy:

Achieved mean weight reduction exceeding 20% (over 24% in some subgroups) in patients with obesity.

Significantly reduced HbA1c in type 2 diabetes patients alongside substantial weight loss.

The overall safety profile is consistent with the GLP-1 receptor agonist class, with no new safety risks identified.

Industry Recognition: Due to its breakthrough data, Retatrutide is recognized as a major advancement in obesity and diabetes treatment, with research published in leading medical journals.